TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11277826

Group type: EXPERIMENTAL
Intervention: Gavestinel (800 mg loading dose + 200 mg every 12 hours for 3 days), n = 701
Number of subjects: 1367

Group type: COMPARATOR
Intervention: Placebo, n = 666
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Gavestinel among patients receiving recombinant tissue‐type plasminogen activator, n = 333
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Gavestinel and placebo overall
Number of subjects: 1367
Study: 9678036

Group type: EXPERIMENTAL
Intervention: Gothenburg hip arthroplasty
Number of subjects: 0
Study: 7741493

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pethidine 1.25 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Comparison of Ketorolac and Pethidine
Number of subjects: 100
Study: 2636483

Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide mouth rinsing, 3 times daily for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3% hydrogen peroxide pocket washing (clinical controlled)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10% hydrogen peroxide Gingivox-strip, 3 times weekly for 3 weeks (clinical controlled)
Number of subjects: 0
Study: 19138596

Group type: EXPERIMENTAL
Intervention: Pingyangmycin sclerotherapy alone
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Surgery with sclerotherapy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pingyangmycin injection followed by histologic examination
Number of subjects: 79
Study: 497075

Group type: EXPERIMENTAL
Intervention: Fentanyl plus droperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 0
Study: 31989592

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training with Electromyostimulation (HIIT-EMS)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Physical Activity Recommendation from WHO
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 69
Study: 31272326

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 1000
Study: 28029656

Group type: EXPERIMENTAL
Intervention: Low lymphocyte-to-white blood cell ratio (LWR)
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: High monocyte-to-white blood cell ratio (MWR)
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: Combination of low LWR and high MWR
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: High neutrophil-to-white blood cell ratio (NWR)
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: High neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: High monocyte-to-lymphocyte ratio (MLR)
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: High platelet-to-lymphocyte ratio (PLR)
Number of subjects: 3243
Study: 25631875

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) plus omeprazole and sucralfate
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional treatment (omeprazole and sucralfate)
Number of subjects: 122
Study: 24050519

Group type: EXPERIMENTAL
Intervention: Treatment initiated within 12 weeks of symptom onset
Number of subjects: 156

Group type: COMPARATOR
Intervention: Private rheumatology practices
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Patients with morning stiffness
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Rheumatologist-related delay
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Total delay from symptom onset until treatment initiation
Number of subjects: 156
Study: 22523532

Group type: EXPERIMENTAL
Intervention: Caloric restriction (25% CR)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caloric restriction plus exercise (CR+EX)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Weight maintenance diet (Control)
Number of subjects: 46
Study: 19036082

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg daily plus pulsed dexamethasone 20 mg 4 days a month
Number of subjects: 103

Group type: COMPARATOR
Intervention: Interferon-alpha 3 MU 3 times a week plus pulsed dexamethasone 20 mg 4 days a month
Number of subjects: 103
Study: 17380263

Group type: EXPERIMENTAL
Intervention: Needle-free injection system (Intraject) with various device configurations
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Device gas mass (chamber pressure) and orifice size
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) and injection site
Number of subjects: 302
Study: 15024305

Group type: EXPERIMENTAL
Intervention: Open intraoperative RFA
Number of subjects: 608

Group type: COMPARATOR
Intervention: Percutaneous RFA
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Patients with cirrhosis
Number of subjects: 608

Group type: COMPARATOR
Intervention: Noncirrhotic patients
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Late complications
Number of subjects: 608
Study: 11435509

Group type: EXPERIMENTAL
Intervention: Supplemental folic acid (15% [3',5'-(2)H(2)] folic acid) during days 1-41, unlabeled during days 42-84, total folate intake of 1.02 or 1.93 micromol/d (450 or 850 microg/d)
Number of subjects: 12
Study: 9923412

Group type: EXPERIMENTAL
Intervention: ATIII concentrate, 70 units/kg within 24 hours of recognition of initial organ dysfunction followed by 50 units/kg 8, 16, 48, and 72 hours later
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ATIII concentrate
Number of subjects: 49
Study: 8072258

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) at a dosage of 5.54 ± 0.81 mg/kg/day for 12 to 60 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment continued for 12 to 60 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment with a dosage of up to 5.5 mg/kg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment with a dosage greater than 5.5 mg/kg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Progressive tapering of CsA after prolonged remission of more than one year
Number of subjects: 36
Study: 3354625

Group type: EXPERIMENTAL
Intervention: Project group structure (subjects participate together on a common task)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Parallel group structure (subjects each have a task)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Project group structure
Number of subjects: 41

Group type: COMPARATOR
Intervention: Parallel group structure
Number of subjects: 41

Group type: COMPARATOR
Intervention: Project group structure and Parallel group structure
Number of subjects: 41
Study: 4886627

Group type: EXPERIMENTAL
Intervention: Short courses of nitrofurantoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short courses of ampicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated bacteriuric women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment (nitrofurantoin or ampicillin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinfections post-treatment
Number of subjects: 0
Study: 31194213

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) tirofiban administration
Number of subjects: 95

Group type: COMPARATOR
Intervention: Intravenous (IV) tirofiban administration
Number of subjects: 95
Study: 29054911

Group type: EXPERIMENTAL
Intervention: Ixazomib-lenalidomide-dexamethasone (IRd)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Placebo-lenalidomide-dexamethasone (placebo-Rd)
Number of subjects: 722
Study: 26101306

Group type: EXPERIMENTAL
Intervention: TeleCARE
Number of subjects: 481

Group type: COMPARATOR
Intervention: Educational brochure
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: TeleCARE (when cost was not a barrier)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: TeleCARE (when cost was a barrier)
Number of subjects: 481
Study: 23810433

Group type: EXPERIMENTAL
Intervention: 40 IU intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21576655

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 230

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 230
Study: 19260129

Group type: EXPERIMENTAL
Intervention: MRI with STIR
Number of subjects: 36

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 36
Study: 17101806

Group type: EXPERIMENTAL
Intervention: Adherence case management intervention with monetary reinforcement (CM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard of care group (SC)
Number of subjects: 90
Study: 15456520

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on day 1 and 8, and cisplatin (60 mg/m2 or 70 mg/m2 for older patients; 80 mg/m2 or 90 mg/m2 for younger patients) in 28-day cycles.
Number of subjects: 0
Study: 10806139

Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg four times a day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined treatment (Terbutaline + Budesonide)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg twice a day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8773158

Group type: EXPERIMENTAL
Intervention: Lisinopril at a dosage ratio of 5:1 (initially captopril 5 mg to lisinopril 1 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Captopril (control group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cost savings analysis
Number of subjects: 56
Study: 1281103

Group type: EXPERIMENTAL
Intervention: Serenoa repens extract (160 mg t.d.) for 3 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3912184

Group type: EXPERIMENTAL
Intervention: Bornaprolol (120, 240 and 480 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol (40, 80 and 160 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29784589

Group type: EXPERIMENTAL
Intervention: HD-tDCS at 2 mA (n=66, 31 active)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: HD-tDCS at 3 mA (n=35, 20 active)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 101

Group type: COMPARATOR
Intervention: Blinding assessment
Number of subjects: 101
Study: 27886017

Group type: EXPERIMENTAL
Intervention: Proprioceptive insoles
Number of subjects: 18

Group type: COMPARATOR
Intervention: Physiotherapy twice a week
Number of subjects: 18
Study: 25450133

Group type: EXPERIMENTAL
Intervention: Subsensory vibratory noise stimulation at 70% of sensory threshold
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subsensory vibratory noise stimulation at 85% of sensory threshold
Number of subjects: 12
Study: 23245226

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (10 sessions of behavioral risk reduction counseling)
Number of subjects: 4296
Study: 22132216

Group type: COMPARATOR
Intervention: Clinician-supported (CL)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Coach-supported (CO)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study: 18192700

Group type: EXPERIMENTAL
Intervention: DDD(R)-pacing
Number of subjects: 50

Group type: COMPARATOR
Intervention: AAI(R)-pacing
Number of subjects: 50
Study: 16644616

Group type: EXPERIMENTAL
Intervention: Inguinal approach
Number of subjects: 32

Group type: COMPARATOR
Intervention: Scrotal approach
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 32
Study: 14640990

Group type: EXPERIMENTAL
Intervention: GH treatment (5 microg/kg per day for 1 month and 10 microg/kg per day for 12-30 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 0
Study: 10363394

Group type: EXPERIMENTAL
Intervention: Educational seminars on generic drugs and computer‐produced prescribing feedback (Intervention group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No seminars and no feedback (Control group)
Number of subjects: 10
Study: 8537523

Group type: EXPERIMENTAL
Intervention: Dynamic CT (DCT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Spiral CT (SCT)
Number of subjects: 31
Study: 1775612

Group type: EXPERIMENTAL
Intervention: Lithium carbonate administration
Number of subjects: 48
Study: 7009946

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 16913

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16913
Study: 31003210

Group type: EXPERIMENTAL
Intervention: Resection of craniopharyngiomas
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Quality of life assessment (SF-36)
Number of subjects: 71
Study: 27767993

Group type: COMPARATOR
Intervention: Souvenaid (uridine monophosphate, docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Souvenaid
Number of subjects: 0
Study: 25748976

Group type: EXPERIMENTAL
Intervention: EHR prompt (alert) indicating specific immunizations recommended at all office visits.
Number of subjects: 7040

Group type: EXPERIMENTAL
Intervention: Staff prompts (reminder sheet) placed on the provider's desk in the exam room.
Number of subjects: 7040

Group type: COMPARATOR
Intervention: Provider prompts (EHR and staff prompts combined)
Number of subjects: 7040
Study: 25439340

Group type: EXPERIMENTAL
Intervention: 24 I.U. oxytocin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22234017

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg capsule orally 1 h before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 30
Study: 19237781

Group type: EXPERIMENTAL
Intervention: Continuous anterior chamber infusion using anterior chamber maintainer (ACM) with balanced salt solution (BSS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ophthalmic viscosurgical device (OVD) with balanced salt solution (BSS)
Number of subjects: 50
Study: 17425871

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/d)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Methylcobalamin (500 microg qd)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Methylcobalamin (500 microg qd) + Folic acid (5 mg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 120
Study: 15353917

Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase plus abciximab
Number of subjects: 150

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase plus abciximab (within <2 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Alteplase (within <2 hours)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase plus abciximab (for time-to-admission intervals > or = 2 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Alteplase (for time-to-admission intervals > or = 2 hours)
Number of subjects: 150
Study: 11576058

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.15 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.22 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.11 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.21 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.25 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium (various doses)
Number of subjects: 60
Study: 9688391

Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation with low-dose human menopausal gonadotrophin and intrauterine insemination (IUI) in stimulated cycles
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI) in natural cycles
Number of subjects: 74
Study: 9211571

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily
Number of subjects: 544

Group type: COMPARATOR
Intervention: Maprotiline 100 mg daily
Number of subjects: 544
Study: 2017529

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6124759

Group type: EXPERIMENTAL
Intervention: anti‐lymphocyte globulin, prednisolone, and azathioprine (3 mg/kg daily after 1 month)
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo preparations
Number of subjects: 43
Study: 30601982

Group type: EXPERIMENTAL
Intervention: Faith, Activity, and Nutrition (FAN) program
Number of subjects: 54
Study: 29048958

Group type: EXPERIMENTAL
Intervention: Shade sails at treatment PRAs
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control PRAs without shade sails
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Shade sails at treatment PRAs in Denver
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Shade sails at treatment PRAs in Melbourne
Number of subjects: 144
Study: 25253583

Group type: EXPERIMENTAL
Intervention: Olmesartan plus CCB
Number of subjects: 5141

Group type: COMPARATOR
Intervention: Olmesartan plus diuretic
Number of subjects: 5141
Study: 23647755

Group type: EXPERIMENTAL
Intervention: Oxford and RTOG guidelines
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Michigan and SCALOP guidelines
Number of subjects: 11

Group type: COMPARATOR
Intervention: PTV-based plans without eLNs
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All contouring guidelines
Number of subjects: 11
Study: 21575941

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Laser vaporization
Number of subjects: 90
Study: 18465345

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 53418

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 53418

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 53418

Group type: COMPARATOR
Intervention: Irradiated patients
Number of subjects: 53418

Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 53418

Group type: COMPARATOR
Intervention: Age at diagnosis
Number of subjects: 53418

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 53418
Study: 17037267

Group type: COMPARATOR
Intervention: At least one dose vs. placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: At least one dose vs. active control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12627416

Group type: EXPERIMENTAL
Intervention: New treatment at high dose
Number of subjects: 146

Group type: COMPARATOR
Intervention: New treatment at low dose
Number of subjects: 146

Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 11148604

Group type: EXPERIMENTAL
Intervention: Carbogen (95% O(2) + 5% CO(2))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 92% O(2) + 8% CO(2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 100% O(2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 97% O(2) + 3% CO(2)
Number of subjects: 16
Study: 8526696

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral quinidine sulfate (300 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral amiodarone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral digoxin/quinidine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous amiodarone and oral quinidine
Number of subjects: 32
Study: 1984814

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theophylline and Salbutamol combined
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6404980

Group type: EXPERIMENTAL
Intervention: Community-based treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital-based treatment
Number of subjects: 0
Study: 30248621

Group type: EXPERIMENTAL
Intervention: Intervention schools with full implementation of the smoking prevention program
Number of subjects: 4161

Group type: EXPERIMENTAL
Intervention: Intervention schools with partial implementation of the smoking prevention program
Number of subjects: 4161

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 4161
Study: 28068613

Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Therapy for Depression (BATD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 34
Study: 26304767

Group type: EXPERIMENTAL
Intervention: Intact immediate‐release/extended‐release oxycodone/acetaminophen 15/650 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intact immediate‐release/extended‐release oxycodone/acetaminophen 30/1,300 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Crushed immediate‐release/extended‐release oxycodone/acetaminophen 30/1,300 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: All subjective effects
Number of subjects: 61
Study: 24803133

Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cuffed tracheal tube
Number of subjects: 50
Study: 22067270

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 122

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 122
Study: 19172130

Group type: EXPERIMENTAL
Intervention: Zinc therapy (20 mg/day elemental zinc for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (oral rehydration solution and feeding advice without zinc)
Number of subjects: 0
Study: 17982923

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (eicosapentaenoic acid and docosahexaenoic acid plus 10 mg vitamin E)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15238051

Group type: EXPERIMENTAL
Intervention: Gambling Urge Questionnaire (GUS)
Number of subjects: 968
Study: 12032413

Group type: EXPERIMENTAL
Intervention: Sodium citrate (C)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 17
Study: 9661646

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day for 4 days)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Long PCR technique
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Short term dexamethasone suppression test
Number of subjects: 117